Donate
Return to Map
Return to Map

Pennsylvania Bladder Cancer Resources

Pennsylvania Department of Health
http://health.pa.gov/Pages/default.aspx

Contact Your State Elected Representative

Bladder Cancer Cases in Pennsylvania at a Glance

  • 4,290

    New State Cases
     

  • 83,190

    New National
    Cases

  • 63,070

    National Cases in Men

  • 20,120

    National Cases in Women

  • 16,840

    National Deaths
     

NCI-Designated Cancer Centers and NCCN Member Institutions

The National Cancer Institute, (NCI) has recognized Cancer Centers for delivering cutting-edge cancer treatments to patients in communities across the United States. There are 71 NCI-Designated Cancer Centers, located in 36 states and the District of Columbia, that are funded by NCI to deliver cutting-edge cancer treatments to patients. Most of the NCI-Designated Cancer Centers are affiliated with university medical centers, although several are freestanding institutions that engage only in cancer research.

The National Comprehensive Cancer Centers (NCCN) are a not-for-profit alliance of 31 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives.

  • NCI Designated Comprehensive Cancer Centers
  • National Comprehensive Cancer Network Member Institution
Abramson Cancer Center

Philadelphia, PA
215-615-5858
Fox Chase Cancer Center

Philadelphia, PA
888-369-2427
Sidney Kimmel Cancer Center – Jefferson Health

Philadelphia, PA
215-503-5692
The Wistar Institute Cancer Center

Philadelphia, PA
215-898-3700
UPMC Hillman Cancer Center

Pittsburgh, PA
412-647-2811

Veterans Administration Hospitals

Altoona - James E. Van Zandt VA Medical Center
Butler VA Health Care System
Coatesville VA Medical Center
Corporal Michael J. Crescenz VA Medical Center
Erie VA Medical Center
Lebanon VA Medical Center
VA Pittsburgh Healthcare System
Wilkes-Barre VA Medical Center

Bladder Cancer Clinical Trials in Pennsylvania

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer LOXO-435 in Patients With Cancer With a Change in a Gene Called FGFR3
See more clinical trials

Philadelphia Walk to End Bladder Cancer

Please join us for this upcoming Walk to End Bladder Cancer and help us raise funds to end this disease.

April 27, 2024

Register to walk

Read Our Stories